Versameb is a Swiss based biotechnology platform company focusing on the optimized local delivery of therapeutic proteins, currently focusing on applications in regenerative medicine. Our vision is to both improve existing therapies as well as develop transformative therapies in entirely new applications in disease indications of high medial need. Versameb is funded by private international investors. We are committed to create substantial long-term value for our patients, shareholders and other stakeholders.
Versameb Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence.
Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut…
| Building | B8 |
|---|---|
| Industry | Biotech |
| Employees | 10 |
| Founding year | 2017 |
Home 
About us 
Offer 
News 
